companion allegedly hacked as reported by Conti ransomware with details: www.inserm-transfert.fr/Inserm Transfert (Paris)
Paris Biopark
7 rue Watt
75013 Paris, France
Tel. +33 1 55 03 01 00
Our departments
Evaluation, proof of concept & Development
Tel. 33 1 55 03 01 69
maturation@inserm-transfert.fr
Intellectual property
Tel. +33 1 55 03 09 84
propriete@inserm-transfert.fr
Collaborative research Funding
Tel. 01 55 03 01 68
projets-collaboratifs@inserm-transfert.fr
Marketing & Industrial partnerships
Health datas & Clinical Research
Tel. 01 55 03 01 18
donnees.sante@inserm-transfert.fr
Licensing & Entrepreneurship
Tel. 01 55 03 01 18
licensing@inserm-transfert.fr
R&D Collaboration
Tel. 01 55 03 01 18
R.D.Partnership@inserm-transfert.frInserm was created in 1964 as a successor to the French National institute of Health.
Inserm is the only public search institution solely focused on human health and medical research in France. It is a public institution with a scientific and technical vocation under the dual protection of the Ministry of health and the Ministry of Research. Similarly to the US National Institutes of Health, Inserm conducts fundamental and translational search projects through 339 search units, ravel by around 13,000 scientists, including 5,100 permanent research faculty members and 5,100 faculty members co-affiliated with university hospitals and medicine faculties. Inserm's laboratories and search units are located all over France, mainly in the largest cities. Eighty percent of Inserm research units are embedded in research hospitals of French universities. in April 2020, Inserm researchers, Dr. Camille Locht and Dr. Jean-Paul Mira, suggested on live telecasting that COVID-19 experimental drugs be tested in Africa, despite the fact that Africa had the fewest cases of the virus in the world. After the comments were widely denounced as racist, Inserm and the two researchers released statements of apology.
Inserm's CEO is chosen by edict upon a proposal of the Ministers of Health and Research, advised by a refresh committee.[3] The CEO since january 2019 is Gilles Bloch, a dr. and researcher specializing in medical imaging.